Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Transcription

1 Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris

2 Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= >75 Years Years < 70 Years AS AR MS MR Multiple Right (Iung et al. Eur Heart J 2003;24: ) European Society of Cardiology Euro Heart Survey

3 Closed-heart commissurotomy Open-heart commissurotomy Percutaneous mitral commissurotomy : K.Inoue 1984

4 Late Results after PMC n= n= Age FU FU % Survival (yrs) (yrs) Cohen (NEJM 1992) ** Orrange (Circulation 1997) ** Ben Farhat (Circulation 1998) * 90* Meneveau (Heart 1998) ,5 7,5 52* 52* Stefanadis (JACC 1998) * 75* Hernandez (Circulation 1999) * 69* Iung (Circulation 1999) ** Palacios (Circulation 2002) ** (*: Survival without intervention **: Survival without intervention and NYHA I / II)

5 Management of Severe Symptomatic Mitral Stenosis Symptomatic MS < 1.5 cm² CI to PMC No Yes CI or high risk for surgery Yes No Favourable anatomical characteristics Unfavourable anatomical characteristics Favourable clinical characteristics Unfavourable clinical characteristics PMC Surgery VHD Guidelines Slide-set 2007 European Society of Cardiology

6 Type of Intervention Native Valve Disease 100% N= % 60% 40% 20% Percut. Int. Valve Repair Bioprosthesis Mech Prosthesis Homograft Autograft 0% AS AR MS MR European Society of Cardiology Euro Heart Survey

7 PMC Across the Five Continents Papeete, Boston, Sao Paulo, Paris, Monastir, Maputo, Ho Chi Minh City (Marijon et al. Arch Cardiovasc Dis 2008;101:611-7)

8 PMC Worldwide: Results Non-Western countries (n=250) Western countries (n=100) p In-hospital cardiac death (%) Mitral regurgitation 3/ Embolism (%) Cardiac tamponade (%) Surgery < 30 days (%) Final valve area (cm²) 1.91 ± ± Final indexed valve area (cm²/m² BSA) 1.22 ± ± 0.29 < Good Immediate Results (Marijon et al. Arch Cardiovasc Dis 2008;101:611-7)

9 Aortic Stenosis INSERM Bichat

10 Severe Symptomatic AS in the Elderly Severe AS : Valve Area 0.6 cm²/m² BSA or Mean Gradient 50 mmhg Symptomatic AS : NYHA Class III or IV or Angina Aortic Stenosis 75 years N=408 No Severe AS (n=114) Severe AS (n=284) NYHA III :106 No Symptoms N=68 Symptoms N=216 NYHA IV : 36 Angina : 148 (Iung et al. Eur Heart J 2005;26: ) No Intervention N=72 (33%) Intervention N=144 (67%) European Society of Cardiology Euro Heart Survey

11 Percutaneous Aortic Valve Implantation Edwards Sapien Medtronic CoreValve Right Subclavian Left Subclavian Transapical Transfemoral (22-24 Fr.) Transfemoral (18 Fr.)

12 Transfemoral Aortic Valve Implantation Edwards Sapien Medtronic CoreValve

13 Transfemoral Aortic Valve Implantation Population Edwards Sapien Medtronic CoreValve Webb et al. Bichat* Source Grube et al. Post CE 18Fr n= Age (yr) Logistic Euroscore (%) AVA (cm²) (* Including 15 cases with Medtronic CoreValve) (Webb et al. Circulation 2009;119: ; Himbert et al. ESC 2009; Source Registry, EuroPCR2009; Grube et al. Circ Cardiovasc Intervent 2008;1:167-75; Post CE Registry EuroPCR 2009)

14 Transfemoral Aortic Valve Implantation 30-Day Results Edwards Sapien Medtronic CoreValve (%) Webb et al. Bichat* Source Grube et al. Post CE 18Fr Implant success Death Neurological complic Myocardial infarction Permanent pacemaker Vascular complications NA 3 AR > 2/ NA (* Including 15 cases with Medtronic CoreValve)

15 Transfemoral Aortic Valve Implantation Survival Edwards Sapien (n=113) Medtronic CoreValve (n=175) No structural valve failure (Webb et al. Circulation 2009;119: )

16 Transfemoral Aortic Valve Implantation Functional Results Symptoms 1-year NYHA class Quality of life Health concepts derived from SF-12 (Webb et al. (Ussia et al. Circulation 2009;119: ) Eur Heart J 2009;30:1790-6)

17 Transapical Aortic Valve Implantation

18 Transapical Aortic Valve Implantation Leipzig (n=161) Bichat (n=31) US registry (n=40) Partner EU (n=67) Source (n=575) Age (yr) Logistic Euroscore (%) Procedural success (%) Surgical conversion (%) Stroke (%) day mortality (%) month survival (%)

19 Transcatheter Aortic Valve Implantation Survival HR [95% CI] Early vs. late 3.4 [ ] Transapical vs. TF 2.2 [ ] Euroscore [ ] HR [95% CI] Renal failure 3.5 [ ] Transapical vs. TF 1.85 [ ] (Himbert et al. ESC 2009) (Webb et al. Circulation 2009;119: )

20 Transcatheter Aortic Valve Implantation Survival 345 procedures in 339 patients (6centres) 30-day mortality 10.4% Transfemoral Transapical Predictors of late mortality procedural sepsis, hemodynamic support, pulmonary hypertension, chronic kidney disease, COPD (Rodés-Cabau et al. J Am Coll Cardiol 2010;55,in press)

21

22 «The Team Approach» SURGEONS CARDIOLOGISTS Anesthesiologists Transcatheter Aortic Valve Implantation Imaging specialists (Echo, CT, MRI) With expertise in the treatment of valve disease (EACTS/ESC/EAPCI Position Statement)

23 Screening - Vascular imaging 16.5 mm 8.3 mm 8.8 mm 8.7 mm 8.0 mm 8.7 mm 8.4 mm

24 Measurement of Aortic Annulus (Messika-Zeitoun et al. J Am Coll Cardiol 2010;55:186-94) A B D Aorta C Left atrium

25 Distance Annulus /Coronary Ostia

26 How to Decrease the Incidence of Significant AR after TAVI? (prosthesis diameter -TEE annulus diameter) Prosthesis-Annulus Cover Index = prosthesis diameter (Detaint et al. JACC Cardiovasc Interv 2009;2:821-7)

27 Screening High-Risk Patients with AS Current Status n= TAVI (%) AVR (%) Med. Therapy (%) Dallas Rotterdam Cleveland Vancouver Milano Paris

28 Indications for TAVI Future Perspectives Technical improvements Smaller and larger versions of existing prostheses Decrease in introducer size New devices Imaging: patient selection, guidance of the procedure Extension of indications Primary deterioration of bioprosthesis TAVI in patients at low(er) risk for surgical AVR Durability Comparative evaluation (randomised trials) Identification of patients who are not candidates to any intervention (poor expected life expectancy / QoL) Risk-benefit (natural history vs. results of interventions) Adapted scores (functional evaluation, psychometric variables )

29 The PARTNER US Trial Population: High Risk/Non-Operable Symptomatic, Critical Calcific Aortic Stenosis n= up to 690 pts Yes Cohort A ASSESSMENT: Operability Total n= 1040 No Cohort B n=350 pts Yes ASSESSMENT: Transfemoral Access No Yes ASSESSMENT: Transfemoral Access No Cohort A TF Powered Independently Cohort A TA Powered to be Pooled with TF 1:1 Randomization 1:1 Randomization 1:1 Randomization Not in Study Trans femoral VS AVR Control Trans apical VS AVR Control Trans femoral VS Medical Management Control Primary Endpoint: All Cause Mortality (Non-inferiority) Primary Endpoint: All Cause Mortality (Superiority)

30 Rationale for the Correction of Ischaemic / Functional MR MR WORSE MR VOLUME OVERLOAD LV DILATION (Levine et al. Curr Cardiol Rep 2002;4:125-9)

31 Indications for Surgery in Ischaemic / Functional MR Chronic Ischaemic MR Patients with severe MR, LV EF > 30% undergoing CABG Patients with moderate MR undergoing CABG if repair is feasible Symptomatic patients with severe MR, LV EF < 30% and option for revascularization Patients with severe MR, LVEF > 30%, no option for revascularization, refractory to medical therapy, and low comorbidity Class IC IIaC IIaC IIbC Functional MR: surgery can be considered only in selected patients with severe symptoms despite optimal medical therapy VHD Guidelines Slide-set 2007 European Society of Cardiology

32 Percutaneous Mitral Valve Repair Prosthetic Ring Annuloplasty

33 Percutaneous Mitral Valve Repair Prosthetic Ring Annuloplasty Mitral valve Tricuspid valve Coronary sinus

34 Percutaneous Mitral Annuloplasty The Monarc Device (Edwards Lifesciences) 8.8F Delivery system Small anchor (Great cardiac vein) Large anchor (CS ostium) 12F Guide catheter and dilator Foreshortening Bridge

35 Percutaneous Mitral Annuloplasty The Carillon Device (Cardiac Dimensions Inc.)

36 Percutaneous Mitral Annuloplasty The PTMA Implant System (Viacor Inc)

37 Percutaneous Mitral Annuloplasty Feasibility / Safety at 30 Day Monarc* Carillon Viacor n= Success implantation (%) In-hospital death (%) Myocardial infarction (%) Tamponade (%) Dissection of coron. sinus (%) 0 6 NA * TCT 2008 Circulation 2009;120: Circ Cardiovasc Intervention 2009;2:277-84

38 Percutaneous Mitral Annuloplasty Efficacy Monarc* n=27 Carillon n=23 Viacor n=9 Pre 1 yr Pre 6 Mo. Pre Post Reduction MR 1/4 (%) NA - 22 ERO ( cm²) NA NA Rvol (ml) NA NA * TCT 2008 Circulation 2009;120: Circ Cardiovasc Intervention 2009;2:277-84

39 Coronary Compression Monarc 50 Patients Baseline & 90-Day Angio 5 Faulty devices 4 Device separation 1 Device slippage 35 Patients No Coronary Vessel Changes 15 Patients (30%) Coronary Vessel Changes ( 3MI s s (1death)) 9 Patients Bridge Compression 5 Patients Anchor Compression 1 Patient Anchor & Bridge Compression Carillon 6 cases (12%) of coronary compression (device recaptured) (Schofer et al. Circulation 2009;120:326-33)

40 CT Imaging Imaging the coronary sinus

41 Percutaneous Mitral Valve Repair Edge-to-Edge Technique in Ischaemic/Functional MR (De Bonis et al. Circulation 2005;112(suppl.I):I-402-8)

42 Probability of Event Free Clinical Success 100% 80% 60% 40% 20% 0% EVEREST : Event Free Clinical Success Patients with Acute Procedural Success (n = 79) 100% 85% 90% 87% 99% 97% 97% 97% 97% 72% 86% 86% 86% 85% 68% 68% 68% Freedom From Death Freedom From Surgery 67% Freedom From Death, Surgery or MR > Time (months) (Feldman. TCT 10/07

43 Conclusion (I) TAVI is a major change in the management of AS Acquired experience Number of potential candidates Present and future challenges Technical improvements Improved safety (imaging, experience ) Thorough evaluation of results Patient selection will be a major issue Be careful in extending use in patients at lower risk Not to go too far in high-risk patients Importance of a team approach and clinical judgment

44 Conclusion (II) The first steps of percutaneous mitral repair have been made in functional / ischaemic MR Pending questions remain on safety and efficacy Results should be carefully evaluated in comparison to surgery and contemporary medical treatment

45 Conclusion (III) Percutaneous valve interventions Are appealing given epidemiologic changes Expand the scope of interventions in high-risk patients Require a multidisciplinary approach at all steps Should be evaluated in the light of other approaches (need for large registries and randomised trials)